Alchemab Therapeutics

Eli Lilly is teaming up with Alchemab to develop a novel antibody-based drug candidate, ATLX-1282, against amyotrophic lateral sclerosis (ALS) based on the biotech’s work drawing on people who have na

Sanofi R&D chief Houman Ashrafian is very sympathetic to the plight of cash-strapped biotechs but has implored companies not to skimp financially on the design and development of their clinical pr

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A